These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 10681741)

  • 1. Fludarabine containing regimen followed by autologous peripheral blood stem cell transplantation in unselected patients with acute myeloid leukemia: a single center experience.
    Mazza P; Amurri B; Palazzo G; Prudenzano A; Pricolo G; Stani L
    Haematologica; 2000 Feb; 85(2):222-4. PubMed ID: 10681741
    [No Abstract]   [Full Text] [Related]  

  • 2. Double reinforcement with fludarabine/high-dose cytarabine enhances the impact of autologous stem cell transplantation in acute myeloid leukemia patients.
    Visani G; Lemoli RM; Isidori A; Piccaluga PP; Martinelli G; Malagola M; Gugliotta L; Bonini A; Bonifazi F; Motta MR; Rizzi S; Castellani S; Tura S
    Bone Marrow Transplant; 2001 Apr; 27(8):829-35. PubMed ID: 11477440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fludarabine combination regimen severely affected peripheral blood stem cell mobilization.
    Laszlo D; Galieni P; Raspadori D; Tozzi M; Lauria F; Martinelli G
    Acta Haematol; 2004; 111(4):228-9. PubMed ID: 15153717
    [No Abstract]   [Full Text] [Related]  

  • 4. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
    Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mini-ICE effectively mobilises peripheral blood stem cells after fludarabine-based regimens in acute myeloid leukaemia.
    Mele A; Leopardi G; Sparaventi G; Nicolini G; D'Adamo F; Guiducci B; Barulli S; Malerba L; Stramigioli S; Talevi N; Politi P; Isidori A; Malagola M; Piccaluga P; Visani G
    Eur J Haematol; 2005 Apr; 74(4):277-81. PubMed ID: 15777338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS).
    Kröger N; Shimoni A; Zabelina T; Schieder H; Panse J; Ayuk F; Wolschke C; Renges H; Dahlke J; Atanackovic D; Nagler A; Zander A
    Bone Marrow Transplant; 2006 Feb; 37(4):339-44. PubMed ID: 16415898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fludarabine and cytarabine combined chemotherapy followed by transfusion of donor blood stem cells for treating relapse of acute leukaemia after allogeneic haematopoietic stem cell transplantation.
    You Y; Li QB; Chen ZC; Li WM; Xia LH; Zhou H; Zou P
    Chin Med J (Engl); 2008 Sep; 121(18):1770-4. PubMed ID: 19080355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early allogeneic blood stem cell transplantation after modified conditioning therapy during marrow aplasia: stable remission in high-risk acute myeloid leukemia.
    Platzbecker U; Thiede C; Freiberg-Richter J; Röllig C; Helwig A; Schäkel U; Mohr B; Schaich M; Ehninger G; Bornhäuser M
    Bone Marrow Transplant; 2001 Mar; 27(5):543-6. PubMed ID: 11313690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 4-hydroperoxycyclophosphamide--purged peripheral blood stem cells for autologous transplantation in patients with acute myeloid leukemia.
    Rizzieri DA; Talbot JT; Long GD; Vredenburgh JJ; Gasparetto C; Smith CS; Colvin MO; Adams D; Morris A; Dodge R; Loftis J; Waters-Pick B; Reese M; Carawan H; Koh LP; Chao NJ
    Biol Blood Marrow Transplant; 2003 Mar; 9(3):183-8. PubMed ID: 12652469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience.
    Pastore D; Specchia G; Carluccio P; Liso A; Mestice A; Rizzi R; Greco G; Buquicchio C; Liso V
    Ann Hematol; 2003 Apr; 82(4):231-5. PubMed ID: 12707726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An antecedent diagnosis of refractory anemia with excess blasts has no influence on mobilization of peripheral blood stem cells and hematopoietic recovery after autologous stem cell transplantation in acute myeloid leukemia.
    Viola A; Falco C; D'Elia R; D'Amico MR; Vicari L; Tambaro FP; Correale P; Laudati D; Palmieri S; Ferrara F
    Eur J Haematol; 2007 Jan; 78(1):41-7. PubMed ID: 17042770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
    Nagler A; Slavin S; Varadi G; Naparstek E; Samuel S; Or R
    Bone Marrow Transplant; 2000 May; 25(10):1021-8. PubMed ID: 10828860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced intensity preparative regimens for allogeneic hematopoietic stem cell transplantation: a single center experience.
    Basara N; Roemer E; Kraut L; Guenzelmann S; Schmetzer B; Kiehl MG; Fauser AA
    Bone Marrow Transplant; 2002 Nov; 30(10):651-9. PubMed ID: 12420203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-myeloablative conditioning regimen of fludarabine, busulfan, anti-thymocyte globulin, and methylprednisolone for allogeneic peripheral blood hematopoietic cell transplantation.
    Lee KH; Lee JH; Lee JH; Kim WK; Chi HS; Lee JS
    Haematologica; 2001 Sep; 86(9):999-1001. PubMed ID: 11532635
    [No Abstract]   [Full Text] [Related]  

  • 15. Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant.
    Devine SM; Sanborn R; Jessop E; Stock W; Huml M; Peace D; Wickrema A; Yassine M; Amin K; Thomason D; Chen YH; Devine H; Maningo M; van Besien K
    Bone Marrow Transplant; 2001 Sep; 28(6):557-62. PubMed ID: 11607768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.
    Kröger N; Perez-Simon JA; Myint H; Klingemann H; Shimoni A; Nagler A; Martino R; Alegre A; Tomas JF; Schwerdtfeger R; Kiehl M; Fauser A; Sayer HG; Leon A; Beyer J; Zabelina T; Ayuk F; San Miguel JF; Brand R; Zander AR
    Biol Blood Marrow Transplant; 2004 Oct; 10(10):698-708. PubMed ID: 15389436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The graft-versus-leukemia effect of nonmyeloablative stem cell allografts may not be sufficient to cure chronic myelogenous leukemia.
    Sloand E; Childs RW; Solomon S; Greene A; Young NS; Barrett AJ
    Bone Marrow Transplant; 2003 Nov; 32(9):897-901. PubMed ID: 14561990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Favourable outcome for patients with myeloid disorders treated with fludarabine-melphalan reduced-intensity conditioning and allogeneic bone marrow stem cell transplantation without the use of T-lymphocyte-depleting antibodies.
    Malladi RK; Peniket AJ; Norton AE; Campbell AJ; Collins GP; Samol J; Eagleton H; Miller E; Morgenstern G; Jones J; Keen-Mcguire A; Barnardo M; Littlewood TJ
    Eur J Haematol; 2004 Aug; 73(2):85-92. PubMed ID: 15245506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of acute lymphoblastic leukemia in adults with seven-drug induction therapy and intensive consolidation with or without autologous stem cell transplantation followed by maintenance therapy. Experience of a single center].
    Doubek M; Mayer J; Korístek Z; Protivánková M; Brychtová Y; Oborilová A; Král Z; Klabusay M; Tomíska M; Buchtová I; Vorlícek J
    Cas Lek Cesk; 2002 Mar; 141(4):122-6. PubMed ID: 12046256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mobilization of peripheral blood stem cells in CLL patients after front-line fludarabine treatment.
    Lysak D; Koza V; Steinerova K; Jindra P; Vozobulova V; Schutzova M
    Ann Hematol; 2005 Jul; 84(7):456-61. PubMed ID: 15770494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.